- Home
- EPM vs SKYE Comparison
EPM vs SKYE Comparison
Compare EPM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPM
- SKYE
- Stock Information
- Founded
- EPM 2003
- SKYE 2012
- Country
- EPM United States
- SKYE United States
- Employees
- EPM N/A
- SKYE N/A
- Industry
- EPM Oil & Gas Production
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- EPM Energy
- SKYE Health Care
- Exchange
- EPM Nasdaq
- SKYE Nasdaq
- Market Cap
- EPM 171.8M
- SKYE 172.9M
- IPO Year
- EPM 1996
- SKYE N/A
- Fundamental
- Price
- EPM $4.73
- SKYE $5.84
- Analyst Decision
- EPM Strong Buy
- SKYE Strong Buy
- Analyst Count
- EPM 1
- SKYE 4
- Target Price
- EPM $8.25
- SKYE $19.25
- AVG Volume (30 Days)
- EPM 252.4K
- SKYE 174.2K
- Earning Date
- EPM 09-10-2024
- SKYE 08-09-2024
- Dividend Yield
- EPM 10.15%
- SKYE N/A
- EPS Growth
- EPM N/A
- SKYE N/A
- EPS
- EPM 0.08
- SKYE N/A
- Revenue
- EPM $82,824,000.00
- SKYE N/A
- Revenue This Year
- EPM N/A
- SKYE N/A
- Revenue Next Year
- EPM $22.21
- SKYE N/A
- P/E Ratio
- EPM $61.57
- SKYE N/A
- Revenue Growth
- EPM N/A
- SKYE N/A
- 52 Week Low
- EPM $4.66
- SKYE $1.44
- 52 Week High
- EPM $9.34
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- EPM 33.60
- SKYE 49.83
- Support Level
- EPM $5.05
- SKYE $5.67
- Resistance Level
- EPM $5.23
- SKYE $6.69
- Average True Range (ATR)
- EPM 0.12
- SKYE 0.68
- MACD
- EPM -0.02
- SKYE 0.10
- Stochastic Oscillator
- EPM 0.00
- SKYE 43.40
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent oil and gas company operating in the US. It is engaged primarily in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas, onshore in the United States. The company's revenues are primarily generated from its crude oil, natural gas and NGL production from the Jonah Field in Sublette County, Wyoming; the Williston Basin in North Dakota; the Barnett Shale located in North Texas; the Hamilton Dome Field in Wyoming; and the Delhi Field in Northeast Louisiana. The revenue generated by the company includes royalty, mineral and working interests.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.